Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*Jennifer Tom, Fang Cai, Jacqueline McBride et al.|Critical Care Medicine|2021Cited by 42
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Norbert Bräu et al.|EClinicalMedicine|2022Cited by 37
Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trialJennifer Tom, Fang Cai, Min Bao et al.|medRxiv|2020Cited by 5